James P. Brady
Responsable des Ressources Humaines chez SPERO THERAPEUTICS, INC.
Postes actifs de James P. Brady
Sociétés | Poste | Début | Fin |
---|---|---|---|
SPERO THERAPEUTICS, INC. | Responsable des Ressources Humaines | - | - |
Historique de carrière de James P. Brady
Anciens postes connus de James P. Brady
Sociétés | Poste | Début | Fin |
---|---|---|---|
UNIQURE N.V. | Responsable des Ressources Humaines | 01/08/2020 | 01/09/2021 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Responsable des Ressources Humaines | 01/04/2015 | 01/08/2020 |
Formation de James P. Brady
Marietta College | Undergraduate Degree |
Harvard University | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Pays-Bas | 2 |
Opérationnelle
Human Resources Officer | 3 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
UNIQURE N.V. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Bourse
- Insiders
- James P. Brady
- Expérience